UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~October~~November 1129, 2018

Oncolix, Inc.

(Exact name of registrant as specified in its charter)

Florida	333-192405	46-3046340
(state or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)
(state or other jurisdictionof incorporation)	(CommissionFile Number)	(IRS EmployerIdentification Number)

14405 Walters Road, Suite 780

Houston, TX

77014

(address of principal executive offices)

(zip code)

281-402-3167 ~~(registrant’s telephone number, including area code)~~

~~___________________________________________~~ (~~former~~registrant’s ~~name~~telephone ~~or former address~~number, ifincluding ~~changed~~area ~~since last report~~code)

_____________________________________________

(former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 71.01 ~~Regulation~~Entry FDinto ~~Disclosure~~a Material Definitive Agreement

~~Oncolix,~~The ~~Inc.~~disclosure ~~(“Oncolix”~~set orforth ~~the~~in ~~“Company”) is furnishing this information pursuant to~~ Item 72.0104 of this Current Report, which information shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information furnished pursuant to Item 7.01 in the Report that is ~~required~~incorporated toherein ~~be disclosed solely~~ by ~~Regulation FD~~reference.

OnItem ~~October 1, 2018, Oncolix and IGL Pharma, Inc~~2.03 ~~(“IGLP”)~~Creation ~~entered~~of ~~into~~ a ~~patent~~Direct ~~and~~Financial ~~technology~~Obligation ~~license~~or ~~agreement~~an ~~and~~Obligation ~~trademark~~under ~~assignment~~an ~~wherein IGLP hereby granted to Oncolix a royalty~~Off-~~bearing,~~Balance ~~sublicensable,~~Sheet ~~exclusive~~Arrangement ~~license to a novel drug for the potential treatment~~ of ~~osteosarcoma, bone metastases and bone marrow ablation. Included in this license are the rights to manufacture, have manufactured, use, import, offer to sell and/or sell products. The license includes~~ a ~~customary upfront payment, milestone payments and royalties on product net sales in exchange for the exclusive global rights to the drug.~~Registrant

~~Osteosarcoma~~The isdisclosure aset ~~fairly~~forth ~~rare disease (U.S. incidence of 800 to 900 patients) that affects both adolescents and adults. While the cure rate~~ in ~~local~~Item ~~osteosarcoma is about 70%, in metastatic disease it is fatal~~2.04 ~~In addition to the need for better therapies to treat the disease, there~~ is ~~also~~incorporated aherein ~~need~~by ~~to reduce the pain associated with bone cancers~~reference. ~~Bone pain is associated with all bone cancers, including bone metastases, which often originate from prostrate and breast cancer.~~

~~Although~~Item ~~osteosarcoma~~2.04 ~~will~~Triggering beEvents ~~our first target, the preclinical data demonstrate~~ that ~~this~~Accelerate ~~drug~~or ~~may~~Increase ~~be effective for the treatment of bone metastases and bone marrow ablation. Bone marrow ablation is~~ a ~~viable~~Direct ~~option~~Financial ~~for~~Obligation ~~many~~or ~~cancers,~~an ~~including~~Obligation ~~leukemia,~~under ~~lymphoma~~an ~~and~~Off-Balance ~~sickle~~Sheet cell anemia. In the case of sickle cell anemia, bone marrow ablation is the only known cure. The current standard for bone marrow ablation is high doses of chemotherapy, which are known to cause significant side effects.Arrangement

~~Item~~Oncolix, 9Inc.01, ~~Financial~~a ~~Statements~~Florida corporation (“Company”), has outstanding convertible notes in the principal amount of $5,407,757. The Convertible Notes bear interest at a rate of 10% per annum, with accrued interest payable commencing April 1, 2019, then on the first day of each calendar month thereafter until maturity. The maturity of the Convertible Notes is August 1, 2019, but commencing on April 1, 2019 and ~~Exhibits~~on the first day of each calendar month thereafter until maturity, the Company is required to redeem an amount of the Convertible Notes equal to 1/5th of the original principal amount, plus 10% of such monthly redemption amount as a bonus.

On November 29, 2018, the Company entered into a variable rate, convertible debt financing in the amount of $83,000. This financing constituted an event of default under the terms of the Convertible Notes. At the holders’ option, the principal amount, accrued interest, and other amounts owing, shall immediately become due and payable. The holders have other rights (bas a result of this event of default and the variable rate, convertible debt financing) ~~Exhibits.~~as set forth in the securities purchase agreement and Convertible Notes that have been filed as exhibits to Forms 8-k filed with the SEC on August 9, 2017 and June 6, 2018.

99Item 8.101 ~~Press~~Other ~~release dated October 11, 2018~~Events

2The Company is halting enrollment in its Phase I clinical trial of Prolanta for the treatment of ovarian cancer as a result of injection site reactions at the current dose level. No other adverse effects or signs of toxicity have been observed for the drug.

~~SIGNATURES~~Two subjects enrolled in the second dosing group, 1 mg per kg of body weight, have experienced inflammation and edema at the injection sites that resulted in their withdrawal from the study. Prolanta is injected subcutaneously daily during the treatment period. The Company believes that a reformulation or alternative dosing method of the drug will be required to continue the clinical evaluation of the drug, and such changes may require additional preclinical toxicity studies and additional clearance by the U.S. Food and Drug Administration. The Company does not have the financial resources at this time to conduct such additional studies.

~~Pursuant~~The toCompany ~~the~~will ~~requirements~~evaluate ofits ~~the~~development ~~Securities Exchange Act of 1934~~plans, ~~the~~including ~~Registrant~~accelerating ~~has~~its ~~duly~~development ~~caused~~timelines ~~this~~for ~~Report~~CycloSam, ~~to be signed on~~ its ~~behalf~~other byproduct ~~the undersigned hereunto duly authorized~~candidate.

	Oncolix, Inc.
Dated: October 11, 2018	By:	/s/ Michael T. Redman
		Michael T. Redman
		Chief Executive Officer

Item 9.01 Financial Statements and Exhibits

3(b) Exhibits.

10.1	Securities Purchase Agreement by and between the Company and Power-Up Lending Group, Ltd., dated 11/27/2018

10.2	Convertible Promissory Note by and between the Company and Power-Up Lending Group, Ltd., dated 11/27/2018

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

	Oncolix, Inc.

Dated: January 2, 2019	By:	/s/ Michael T. Redman
		Michael T. Redman
		Chief Executive Officer

Filing Compare · Oncolix, Inc.